Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesPathogenesis of human immunodeficiency virus infectionAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesThe complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solutionAnti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactionsCharacterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution.Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralizationAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domainsNeutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodiesGenetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequencesResistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions.The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsStructural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.
P2860
Q24561905-91AB2884-5825-4FF2-9640-79D7154EEFBFQ24634681-468F18FF-179E-492F-B76D-9E0C2D153B5DQ27469855-F98B2DFF-44D4-4FB6-863C-ACCC5BBC7A1EQ27489000-3B3255D6-5289-414D-89C9-CB01E2DF5919Q27729741-E9074248-5A9B-44C0-B08E-B45E8677EE63Q28378840-26AE281F-3407-41F2-901B-5848196AF5ABQ28646835-840A14CC-2227-408B-9E3E-469B79BCC18DQ30417262-C3475B35-9D5F-4B5D-BAF5-3E30863603C9Q30420728-508F5BF0-930B-4657-8CD8-CA9B4C592BBCQ31911259-44F611BD-0CC9-4C9D-BE15-84C4C12B428EQ33782556-4903EEBA-5783-4D54-8626-C374860A30EAQ33853226-42215D40-274B-44B3-89AD-F05D38460794Q33870236-0024DD99-3EF7-4BBB-98B0-ED814E552985Q34461554-16D439B7-4EE6-490A-8BB5-5D6F6DD93034Q35837553-D9442FB0-7FF4-4E3E-8919-E88BB037C199Q35841480-71F9B5A3-0B94-4D1C-9089-F0013D33BB27Q35854300-99DC8AC7-3404-4760-9A35-4FA0F4105C10Q35857331-7A5EB5E1-19B9-434F-849B-20E836B9BF41Q35870879-45E5FEF3-174C-4A39-A5A2-05A7E27996E6Q35872545-5762C75D-3ECA-424F-8307-87DDCB596A7FQ35894716-C78657B1-646E-4EB8-95FD-125174F476E0Q35898116-285E8452-E99B-4F91-862D-81FBDACDCD10Q36365085-F6ADB8FD-03E7-4486-8B15-39B32D84B26EQ36366296-60DAC23E-3D93-498F-ACD0-01AF5FECCEEBQ36380741-E7AA6F05-D616-4732-B5B5-F0A8CFAF2DE7Q36600380-0D520775-05CC-494F-96BA-77C4FE19DF08Q36620087-703FD922-A050-4F36-A590-2AF478AE5245Q36628256-CE942660-35C0-4AB3-8880-FD01BD3070A3Q36634439-25B74880-39B0-4906-AB01-4CAB082508C6Q36637273-2E772AE9-02A1-4391-8F39-200CF561D9E6Q36651761-EE4BEE2B-C7D6-4719-8A58-3142865EDFDEQ36652422-B2204F35-763F-4657-A14A-F75722DAF25BQ36676729-E2756A58-A366-40DC-A3D8-FD34AE3BE610Q36797568-349145A4-EFB2-4E66-8A18-32FD8C73A9C1Q36954472-265C487A-F6D1-481B-9B82-7118A9690B42Q37072702-8EDFE8F1-7414-45B7-BDEB-6F5B18BD713CQ37084521-A4D22DFB-5BFC-47EB-99DF-715F6F05D183Q39454698-416CB6F4-1396-4747-8D7B-2C77EC09DA4FQ39485924-2B92932C-2249-4837-BE41-3D5006753DB7Q39873568-0E0969CA-DA9B-4853-991B-AA5EEF0397E6
P2860
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Synergistic interaction betwee ...... deficiency virus type I gp120.
@en
type
label
Synergistic interaction betwee ...... deficiency virus type I gp120.
@en
prefLabel
Synergistic interaction betwee ...... deficiency virus type I gp120.
@en
P2093
P1433
P1476
Synergistic interaction betwee ...... deficiency virus type I gp120.
@en
P2093
P304
P356
10.1016/0042-6822(92)90249-O
P407
P577
1992-12-01T00:00:00Z